Dr Advani discusses the long-term toxicity data from the Phase III E1910 trial, which evaluated the combination of blinatumomab with chemotherapy in adults with Philadelphia chromosome-negative (Ph-) B-acute lymphoblastic leukaemia (ALL).

The study demonstrated that blinatumomab was well tolerated, with manageable toxicities, including a higher incidence of neurological events in the blinatumomab arm.

Factors such as age, gender, BMI, and number of cycles of blinatumomab were found to influence toxicity profiles, with no significant differences in survival outcomes.